Grünenthal Meds was established in August 2023, as part of a Joint Venture Collaboration between Grünenthal and Kyowa Kirin.
Headquartered in the UK, we are responsible for managing a portfolio of 13 medicines across six key therapeutic areas, including cancer pain, constipation, and bone health. Through a network of affiliates and key partners, we are bringing these important products to patients in need around the globe.
Company Details
- Employees
- 52
- Address
- Galashiels, Selkirkshire, Gb
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.grunenthalmeds.com
- HQ
- Galashiels, Selkirkshire
Grünenthal Meds Questions
Grünenthal Meds's website is http://www.grunenthalmeds.com
Grünenthal Meds's LinkedIn profile is https://uk.linkedin.com/company/grunenthal-meds
Grünenthal Meds has
52 employees.
View email and phone details for 52
employees at Grünenthal Meds.
Grünenthal Meds's industry is
Pharmaceutical Manufacturing
Grünenthal Meds's top competitors are
Kyowa Kirin International Plc.,
Sanofi,
Noveeda,
Nrg-Office,
Afrscm - Association Francophone De Supply Chain Management,
Grünenthal Group,
Grünenthal Latam,
Averitas Pharma,
Grünenthal Italia,
Pfizer.
Grünenthal Meds's categories are Pharmaceutical Manufacturing
